Amisulpride in the Treatment of Somatoform Disorders

Saddichha, Sahoo; Goswami, Kausik; Vishnuvardhan, Gopalkrishnan

doi:10.3109/00048674.2011.585455

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, the 5-HT7 antagonistic activity provides a key antidepressant effect, and several trials empirically substantiated antidepressant properties of amisulpride 3–6 . In addition, a growing body of evidence has suggested that somatic complaints, including pain, somatoform disorders, and chronic fatigue, could benefit from analgesic effects of antipsychotics and amisulpride per se 12–14 . Nevertheless, these accumulated pieces of evidence mainly cover adult samples.…”

mentioning

confidence: 99%

“…[3][4][5][6] In addition, a growing body of evidence has suggested that somatic complaints, including pain, somatoform disorders, and chronic fatigue, could benefit from analgesic effects of antipsychotics and amisulpride per se. [12][13][14] Nevertheless, these accumulated pieces of evidence mainly cover adult samples. Despite these advancements, amisulpride is not approved by the Food and Drug Administration as an antipsychotic in the United States.…”

mentioning

confidence: 99%

See 1 more Smart Citation

When to Use Amisulpride in Adolescents

Tunçtürk¹,

Ermiş²,

Sağlam³

et al. 2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

Purpose/Background: Despite increasing interest in amisulpride, current knowledge about its use in the pediatric population is scarce. This chart review aimed to investigate the use of amisulpride in a naturalistic adolescent population.Methods/Procedures: Electronic medical records of a tertiary care adolescent inpatient unit were screened between January 2015 and April 2021. Sociodemographic data and all clinical information were collected via data collection forms, and targeted symptoms were obtained from patients' files. Patients with early-onset psychotic disorders (n = 58), bipolar I disorder (n = 29), major depressive disorder (n = 14), and other psychiatric diagnoses (n = 9) were included. Treatment response was defined as a Clinical Global Impression-Improvement of at least much improvement after treatment.Findings/Results: Median titration rate of amisulpride was 400 mg/wk, and the maximum administered daily dose ranged between 100 and 1200 mg/d. The maximum daily dose and number of previous antipsychotics were higher in the early-onset psychotic disorder group. Persistent positive symptoms and resistance to previous treatments were leading causes for amisulpride treatment. Other indications were also impulsive/ disruptive behaviors, antipsychotic adverse effects, depressive symptoms, somatic complaints, and abnormalities in liver function tests. Finally, patients with lower daily treatment doses and more previous antipsychotic trials are less likely to benefit from the treatment.Implications/Conclusions: Persistent psychotic/mood symptoms, impulsive/ disruptive behaviors, and abnormalities in liver function tests were reasons for the amisulpride treatment in adolescents. Randomized placebocontrolled trials are needed to evaluate the efficacy and safety of the treatment in adolescents.

show abstract

mentioning

confidence: 99%